Business Context and Reporting Period
This Form 8-K is a current report filed by Eterna Therapeutics Inc. (trading symbol: ERNA) on February 7, 2025. The filing addresses corporate governance matters regarding the scheduling of the 2025 Annual Meeting of Stockholders and the associated deadlines for shareholder proposals and director nominations.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance notifications and does not contain financial performance data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the Board of Directors setting the date for the 2025 Annual Meeting for May 1, 2025. This date is more than 30 calendar days before the one-year anniversary of the 2024 annual meeting.
Guidance, Outlook, and Corporate Actions
- Annual Meeting Date: May 1, 2025.
- Deadlines for Stockholder Action: To bring business before the Annual Meeting or nominate a director, stockholders must provide notice by the close of business on February 23, 2025.
- Proxy Proposals: Proposals intended for inclusion in the proxy statement under Rule 14a-8 must also be received by the close of business on February 23, 2025.
- Submission Address: Notices and proposals must be sent to Eterna Therapeutics Inc., Attention: Secretary, 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141.
Key Facts for Investor Verification
- Verify the deadline of February 23, 2025, for submitting director nominations or stockholder proposals.
- Confirm the Annual Meeting date of May 1, 2025, for calendar planning.
- Note that this filing contains no financial results; investors should refer to the most recent 10-K or 10-Q for financial data.
- Ensure all submissions conform to the Company's Bylaws and Exchange Act regulations.